URGN · Bull vs Bear

The case for and the case against UroGen Pharma Ltd., each point drawn from public SEC filings — who’s buying, the red flags, and the health score. No opinion, no price call. Read both sides, then pick yours.

the bull case // 1

Strong price momentum

+84.6% vs 200-day

SEC XBRL

the bear case // 6

Going-concern warning

Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.

SEC filing ↗

Bankruptcy-risk zone

Altman Z-Score is in the distress zone (-2.66).

SEC filing ↗

Earnings-manipulation risk

Beneish M-Score (-1.42) is above the threshold — a screen for earnings-quality review, not an accusation (fast growers can trip it).

SEC filing ↗

Weak fundamentals

Piotroski F-Score of 1/9 — most quality checks are failing.

SEC filing ↗

One-sided insider selling

4 insider sales and no open-market buys in the recent window.

SEC filing ↗

Insiders are selling

4 insider sales recently with no offsetting open-market buys.

SEC Form 4 →

where do you land on URGN?

Bull Bear

Saved on this device. Your call, from the evidence above — not a recommendation.

Educational only — not financial adviceand never a recommendation to buy or sell. Both sides are built from public SEC filings (Form 4, STOCK Act, 13F, XBRL financials), which lag 40–90 days; absence of a red flag is not a clean bill of health.